New study aims to transform understanding The ‘SCN1A Horizons Natural History Study’ is anticipated to be a milestone in transforming understanding of SCN1A epilepsies, including Dravet Syndrome, one of the most complex and severe developmental and epileptic conditions. The nationwide study aims to define the seizure, neurodevelopmental, and behavioural characteristics of SCN1A-related epilepsies in 400…
Category: Epilepsy
Epilepsy associated with CDKL5 Deficiency Disorder
European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder 31 July 2023: Marinus Pharmaceuticals announced that the European Commission (EC) has granted approval of ZTALMY® (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to…
Could new materials lead to implantable treatments for epilepsy?
Breakthrough research on materials may help new types of probes be safely implanted in the brain. Bioengineering researchers from the University of Glasgow have investigated new dissolvable coatings which could help safely guide flexible implants into brains to help regulate temporal lobe epilepsy. The development of the material, outlined in an early-view paper in the…
Grant to explore new epilepsy treatment for Tuberous Sclerosis Complex (TSC)
Dr Felix Chan awarded £174k grant to study Tuberous Sclerosis Complex (TSC) and epilepsy by Epilepsy Research UK. The new study will investigate lysine metabolism as a therapeutic target for epilepsy in TSC Research designed with TSC and epilepsy patient community through Tuberous Sclerosis Association and Epilepsy Research UK. A researcher based in Aston Institute for…
‘Microbot’ development could help treat seizures
University of Glasgow researchers are part of a new project which is setting out to develop tiny injectable robots capable of predicting and mitigating epileptic seizures. The project, called CROSSBRAIN, is led by Tor Vergata University of Rome in Italy and is funded by the European Innovation Council. Over the course of the next four…
FINTEPLA®▼ (fenfluramine) oral solution approved in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)
UCB’s FINTEPLA®▼ (fenfluramine) oral solution has been approved in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients two years of age and older.1 The approval by the European Commission (EC) was based on safety and efficacy data from a…
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)
FINTEPLA®▼ (fenfluramine) oral solution recommended for approval in the EU UCB, a global biopharmaceutical company, announced on 19th December 2022 that FINTEPLA®▼ (fenfluramine) oral solution has been recommended for marketing authorisation in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for…
New method of examining the brain’s electrical signals
Method could hold the key to better treatment of epilepsy and schizophrenia Researchers are exploring new ways to ‘listen’ to and record electrical signals emitted from brain cells Findings could be used to help treat conditions like epilepsy and schizophrenia Project will use newly developed nanomaterials to keep removed samples of brain healthy for longer…
Cenobamate (ONTOZRY®) now available in The Netherlands
Angelini Pharma, an international pharmaceutical company part of the privately held Italian Angelini Group announced on 4 April 2022 that ONTOZRY® (cenobamate) is now available in the Netherlands for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adults patients who have not been adequately controlled despite an history of treatment with…
